Eli Lilly, Novo Nordisk and Boehringer Ingelheim: How pharmaceutical stocks will perform in 2023

Eli Lilly, Novo Nordisk and Boehringer Ingelheim: How pharmaceutical stocks will perform in 2023

According to a report by www.deraktionaer.de,

In 2023, Eli Lilly and Novo Nordisk stocks will be among the top performers in the pharmaceutical sector as they are on the fast track with their diabetes and weight loss products. Boehringer Ingelheim also wants to secure a piece of the booming market in the future and is relying on Gubra's expertise, among other things.

The new research and licensing agreement between Gubra and Boehringer Ingelheim to explore novel peptides for the treatment of obesity has the potential to take obesity treatment to the next level for the benefit of patients worldwide. Based on the new partnership, Gubra has the prospect of receiving payments of up to 144 million euros from Boehringer Ingelheim, consisting of success-related development and marketing milestones as well as license fees.

This partnership has the potential to have a major impact on the market, particularly in the area of ​​treating obesity and other metabolic diseases. The milestone payments of up to 144 million euros can significantly improve Gubra's financial situation and increase the company's market potential. In addition, Boehringer Ingelheim's investment in Gubra's research and development shows that there is high interest in innovative approaches to combat metabolic diseases.

Overall, the new partnership points to a promising future for Gubra and strengthens the company's position as a reliable drug researcher in the pharmaceutical industry. This could have a long-term positive impact on consumers as new treatments for metabolic diseases are developed. The Gubra share could therefore serve as an interesting portfolio addition for speculative investors.